Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
DATA GRAPHICS | Product Development

Molecular glue degraders: moving beyond IMiDs

Technologies unraveling the relationships between glue structures and conformational changes are opening up new targets and E3 ligases

By Danielle Golovin, Staff Writer
November 11, 2022 10:27 PM UTC

The molecular glue degrader field is evolving from tinkering with serendipitously discovered IMiDs to systematic discovery of compounds that can access new protein targets and E3 ligases.

In the eight years since the discovery that Celgene’s immunomodulatory imide drugs (IMiDs) degrade oncogenic transcription factors by “gluing” them to E3 ubiquitin ligases, over a dozen biotechs have cropped up to develop molecular glue degraders, mostly for cancer...

Get Unlimited Access
Continue reading with a free trial.
Start a Free TrialLog In
Or Purchase This Article

BCIQ Company Profiles

A-Alpha Bio Inc.

Abbvie Inc.

Ambagon Therapeutics Inc.

Amphista Therapeutics Ltd.

Biotheryx Inc.

Bristol Myers Squibb Co.

C4 Therapeutics Inc.